Shield’s Feraccru accepted for review in the US
Shield Therapeutics’ iron deficiency drug Feraccru has been accepted for review by the US Food and Drug Administration (FDA).
Read More
Tag: Ferracru
Norgine buys rights to sell Shield’s iron deficiency therapy
Norgine has signed a deal with Shield Therapeutics allowing it to commercialise iron deficiency therapy Feraccru in Europe, Australia and New Zealand.
Read More
SMC welcomes Jevtana but turns four others away
Patients in Scotland with advanced prostate cancer will be able to get routine access to Sanofi Genzyme’s Jevtana on the NHS after all, after cost regulators changed track and endorsed the drug as a cost effective use of resources.
Read More
- Ipsen announces new data on Dysport in neurological disease
- PMGroup Worldwide Ltd welcomes MAD World Summit
- Argenx receives review from FDA for VYVGART in seronegative gMG
- Nuclera extends Series C funding to advance antibody engineering
- Cellistic launches new iPSC-based platforms to expand immuno-oncology therapies
